Corvus Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
CRVS Corvus Pharmaceuticals Inc
CPFXF Copper Fox Metals Inc
DDAIF Daimler AG
REI Ring Energy Inc
CZSVF Goldcore Resources Ltd
AAPL Apple Inc
PMBC Pacific Mercantile Bancorp
MSFT Microsoft Corp
O Realty Income Corp
CRLBF Cresco Labs Inc

Health Care : Biotechnology | Small Cap Value
Company profile

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company's lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.

Closing Price
Day's Change
-0.10 (-2.79%)
B/A Size
Day's High
Day's Low

10-day average volume:



6 providers
February 18, 2021
Thinking about buying stock in Avinger, Rigel Pharmaceuticals, Vistagen Therapeutics, Bio-Path, or Corvus Pharmaceuticals?

InvestorsObserver issues critical PriceWatch Alerts for AVGR, RIGL, VTGN, BPTH, and CRVS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the...(PR Newswire)

February 17, 2021
Corvus Pharmaceuticals Announces Closing of Public Offering of Common Stock

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the completion of its previously announced underwritten public offering of 9,783,660 shares of its common stock, which includes 1,212,231 shares...(Globe Newswire)

February 12, 2021
Corvus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 8,571,429 shares of its common stock at a price to the public of $3.50 per share, for gross...(Globe Newswire)

February 11, 2021
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be...(Globe Newswire)

February 04, 2021
Corvus Pharmaceuticals Initiates Phase 3 Clinical Trial of CPI-006 for Patients with COVID-19

Novel immunotherapy approach designed to stimulate immune response by activating B cells to enhance polyclonal antibody production and potentially reduce hospitalization and progression to respiratory failure (Globe Newswire)

November 30, 2020
Corvus Announces Upcoming CPI-818 Data Presentations at the American Society of Hematology (ASH) Annual Meeting & Exposition

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that new data on CPI-818, the Company's ITK inhibitor, will be presented at the 62 American Society of Hematology (ASH) Annual Meeting &...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.